Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria :~* Participants genetically diagnosed with hoFH.~* Participants treated with optimal dose of statin +/- other lipid modifying therapies (LMTs), or non-statin LMTs if statin-intolerant at stable dose(s) for at least 4 weeks.~* A signed informed consent indicating parental permission with or without participants assent.~* For participants on apheresis, currently undergoing stable LDL apheresis therapy prior to the screening visit (Week -2) and had initiated apheresis treatment for at least 6 months.~Exclusion criteria:~* Participants with LDL-C \<130 milligram per deciliter \[mg/dL\] (3.37 millimoles per liter \[mmol/L\]) obtained during the screening period after the participant had been on stable apheresis procedure or LMT (i.e., stable optimal dose of statin ± other stable LMTs, or stable non statin LMTs in statin-intolerant participants) treatment for at least 4 weeks.~* Participants with BW \<25 kg.~* Participants aged 8 to 9 years not at Tanner Stage 1 and participants aged of 10 to 17 years not at least at Tanner Stage 2 in their development.~* Participants with uncontrolled Type 1 or 2 diabetes mellitus.~* Participants with known uncontrolled thyroid disease.~* Participants with uncontrolled hypertension.~* Participants who will receive statin de novo during the run-in period.~* Fasting triglycerides greater than (\>) 350 mg/dL (3.95 mmol/L) at the screening visit.~* Severe renal impairment (i.e., estimated glomerular filtration rate \<30 milliliter per minute/1.73 meter square) at the screening visit.~* Alanine aminotransferase or aspartate aminotransferase \>2 \* upper limit of normal (ULN) at the screening visit.~* Creatine phosphokinase \>3 \* ULN at the screening visit.~The above information was not intended to contain all considerations relevant to a participants potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Alirocumab (Type: EXPERIMENTAL): Participants with BW less than (\<) 50 kilograms (kg) received subcutaneous (SC) injection of alirocumab 75 mg Q2W for 48 weeks. Alirocumab dose was up-titrated to 150 mg Q2W from Week 12 in case of increase in BW with BW greater than or equal to \[\>=\] 50 kg.~Participants with BW \>=50 kg received SC injection of alirocumab 150 mg Q2W for 48 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).